Federal Register / Vol. 74, No. 172 / Tuesday, September 8, 2009 / Notices 46231 

Drug Schedule 

Tilidine (9750) ............................... I 

Trimeperidine (9646) .................... I 

1-Phenylcyclohexylamine (7460) II 

1- 

Piperidinocyclohexanecarbonitrile (8603).

II 

Alfentanil (9737) ........................... II 

Alphaprodine (9010) ..................... II 

Amobarbital (2125) ....................... II 

Amphetamine (1100) .................... II 

Anileridine (9020) ......................... II 

Bezitramide (9800) ....................... II 

Carfentanil (9743) ......................... II 

Coca Leaves (9040) ..................... II 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Dextropropoxyphene, bulk (nondosage forms) (9273).II 

Dihydrocodeine (9120) ................. II 

Dihydroetorphine (9334) ............... II 

Diphenoxylate (9170) ................... II 

Ethylmorphine (9190) ................... II 

Etorphine Hcl (9059) .................... II 

Fentanyl (9801) ............................ II 

Glutethimide (2550) ...................... II 

Hydrocodone (9193) ..................... II 

Hydromorphone (9150) ................ II 

Isomethadone (9226) ................... II 

Levo-alphacetylmethadol (9648) .. II 

Levomethorphan (9210) ............... II 

Levorphanol (9220) ...................... II 

Lisdexamfetamine (1205) ............. II 

Meperidine (9230) ........................ II 

Meperidine intermediate-A (9232) II 

Meperidine intermediate-B (9233) II 

Meperidine intermediate-C (9234) II 

Metazocine (9240) ........................ II 

Methadone (9250) ........................ II 

Methadone intermediate (9254) ... II 

Methamphetamine (1105) ............ II 

Methylphenidate (1724) ................ II 

Metopon (9260) ............................ II 

Moramide intermediate (9802) ..... II 

Morphine (9300) ........................... II 

Nabilone (7379) ............................ II 

Opium, raw (9600) ....................... II 

Opium extracts (9610) .................. II 

Opium fluid extract (9620) ............ II 

Opium tincture (9630) .................. II 

Opium, granulated (9640) ............ II 

Oxycodone (9143) ........................ II 

Oxymorphone (9652) ................... II 

Pentobarbital (2270) ..................... II 

Phenazocine (9715) ..................... II 

Phencyclidine (7471) .................... II 

Phenmetrazine (1631) .................. II 

Phenylacetone (8501) .................. II 

Piminodine (9730) ........................ II 

Powdered opium (9639) ............... II 

Racemethorphan (9732) .............. II 

Racemorphan (9733) ................... II 

Remifentanil (9739) ...................... II 

Secobarbital (2315) ...................... II 

Sufentanil (9740) .......................... II 

Thebaine (9333) ........................... II 

The company plans to import small 

quantities of the listed controlled 

substances for the National Institute on 

Drug Abuse (NIDA) for research 

activities. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a) 

and determined that the registration of 

Research Triangle Institute to import the 

basic class of controlled substance is 

consistent with the public interest and 

with United States obligations under 

international treaties, conventions, or 

protocols in effect on May 1, 1971, at 

this time. DEA has investigated 

Research Triangle Institute to ensure 

that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic classes of controlled 

substances listed. 

Dated: August 28, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–21534 Filed 9–4–09; 8:45 am] 

BILLING CODE 4410–09–M 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on July 21, 2009, 

Chemic Laboratories, Inc., 480 Neponset 

Street, Building 7, Canton, 

Massachusetts 02021, made application 

by renewal to the Drug Enforcement 

Administration (DEA) as a bulk 

manufacturer of Cocaine (9041), a basic 

class of controlled substance listed in 

schedule II. 

The company plans to manufacture 

small quantities of the above listed 

controlled substance for distribution to 

its customers for the purpose of 

research. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substance, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than November 9, 2009. 

Dated: August 28, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–21521 Filed 9–4–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on July 8, 2009, Cody 

Laboratories, 601 Yellowstone Avenue, 

Cody, Wyoming 82414, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the basic classes of controlled 

substances listed in schedules I and II: 

Drug Schedule 

Dihydromorphine (9145) ............... I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Amobarbital (2125) ....................... II 

Pentobarbital (2270) ..................... II 

Secobarbital (2315) ...................... II 

Phenylacetone (8501) .................. II 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Diphenoxylate (9170) ................... II 

Ecgonine (9180) ........................... II 

Hydrocodone (9193) ..................... II 

Meperidine (9230) ........................ II 

Methadone (9250) ........................ II 

Morphine (9300) ........................... II 

Oxymorphone (9652) ................... II 

Alfentanil (9737) ........................... II 

Remifentanil (9739) ...................... II 

Sufentanil (9740) .......................... II 

Fentanyl (9801) ............................ II 

The company plans on manufacturing 

the listed controlled substances in bulk 

for sale to its customers. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than November 9, 2009. 


jlentini on DSKJ8SOYB1PROD with NOTICES